help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 44, No. 6 1190-1193
doi:10.1210/jcem-44-6-1190
Copyright © 1977 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ABSHAGEN, U.
Right arrow Articles by OELKERS, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ABSHAGEN, U.
Right arrow Articles by OELKERS, W.

Increased Plasma 11-Deoxycorticosterone During Spironolactone Medication

U. ABSHAGEN*, S. SPÖRL, M. SCHÖNESHÖFER and W. OELKERS

Department of Internal Medicine and Department of Clinical Pharmacology, Freie Universität Berlin Berlin, W. Germany

* Reprint requests to: U. Abshagen, Department of Internal Medicine, Klinikum Steglitz, Freie Universitat Berlin, Hindenburgdamm 30, D-1000 Berlin 45, W. Germany.

The increase of plasma deoxycorticosterone (DOC) levels after administration of spironolactone is a real effect and not due to crossinterference of the drug or its metabolites with the DOC-assay. This is proved by in vitro and in vivo results. Of all the metabolites only canrenone interferes to some extent with DOC after liquidliquid- extraction and paper chromatography. The antiserum, however, is so highly specific, that the final cross-interference of the total procedure amounts to less than 2% of the DOC plasma levels. Moreover, in patients with Addison's disease only a very small increase of DOC plasma levels can be observed after administration of spironolactone in contrast to normal subjects.

Supported in part by the Deutsche Forschungsgemeinschaft (Ab 28/1).

Received August 30, 1976.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1977 by The Endocrine Society